Allakos INC Form 4 insider transactions

BVF Partners L.P. and related entities report the disposition of their entire holdings in Allakos Inc. common stock due to the merger with Concentra Biosciences, LLC.

Allakos President Adam Tomasi disposed of shares and stock options following the merger agreement with Concentra Biosciences, receiving $0.33 per share.

Director Thomas Dolca reports the cancellation of stock options in Allakos Inc. due to the merger agreement with Concentra Biosciences, LLC.

Allakos CFO Radford Baird disposed of common stock and stock options following the merger agreement with Concentra Biosciences.

Director Graham Neil Murray Hamilton reports cancellation of stock options due to merger agreement.

Director Paul Edward Walker reports the disposal of Allakos Inc. shares and stock options due to the merger agreement with Concentra Biosciences, receiving $0.33 per share.

Director Amy L. Ladd reports the cancellation of stock options due to the merger agreement between Allakos Inc., Concentra Biosciences, LLC, and Concentra Merger Sub III, Inc.

Director James Steven P. reports the cancellation of several stock options in Allakos Inc. following the merger agreement with Concentra Biosciences, LLC and Concentra Merger Sub III, Inc.

Director Robert E. Andreatta reports the cancellation of several stock options related to the Allakos Inc. merger with Concentra Biosciences, LLC.

Allakos CEO Robert Alexander disposed of shares and options due to the merger agreement with Concentra Biosciences, receiving $0.33 per share.

Allakos Inc. President Adam Tomasi sold 20,017 shares of common stock on March 5, 2025, to cover tax withholding obligations related to vesting RSUs.

Allakos Inc. CEO Robert Alexander sold 31,370 shares of common stock on March 6, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).

Harlan Baird Radford, CFO of Allakos Inc., sold 14,161 shares of common stock on March 5, 2025, to satisfy tax withholding obligations related to the vesting of RSUs.

Allakos Inc. President Adam Tomasi sold 21,116 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Allakos' Chief Financial Officer, Harlan Baird Radford, sold 13,138 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Allakos CEO Robert Alexander sold 32,466 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Allakos Inc.'s Chief Medical Officer, Lee Chin Hyok, sold 10,634 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Allakos Inc. CEO Robert Alexander sold 37,311 shares of common stock on September 11, 2024, to satisfy tax withholding obligations related to the vesting of restricted stock units.

Chin Hyok Lee, Chief Medical Officer of Allakos Inc., sold 45,320 shares of common stock on September 9, 2024, to satisfy tax withholding obligations related to vesting RSUs.

Allakos Inc. President Adam Tomasi sold shares to cover tax obligations related to vesting RSUs, according to a recent SEC filing.

Harlan Baird Radford, CFO of Allakos Inc., sold 13,665 shares of common stock on September 6, 2024, to satisfy tax withholding obligations related to the vesting of RSUs.

Harlan Baird Radford, CFO of Allakos Inc., sold 87,064 shares of common stock at an average price of $1.01 on June 28, 2024.

Allakos CEO Robert Alexander sold 37,525 shares of common stock on June 6, 2024, to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).

Allakos Inc. President Adam Tomasi sold 24,749 shares of common stock on June 7, 2024, to satisfy tax withholding obligations related to vesting RSUs.

H. Baird Radford, CFO of Allakos Inc., sold 14,565 shares of common stock on June 4, 2024, to satisfy tax withholding obligations related to vesting RSUs.

Director Paul Edward Walker acquired 41,000 stock options in Allakos Inc. on May 24, 2024, according to a recent SEC filing.

Director Amy L. Ladd acquired 41,000 stock options in Allakos Inc. on May 24, 2024, at an exercise price of $1.42.

Director Neil Murray Hamilton Graham acquired 41,000 stock options in Allakos Inc. on May 24, 2024.

Director Robert E. Andreatta acquired 41,000 stock options in Allakos Inc. on May 24, 2024, according to a Form 4 filing with the SEC.

Director Steven P. James acquired 41,000 stock options in Allakos Inc. on May 24, 2024.